MEDIUM confidence: 100% data completeness, but the composite (58) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-08-09.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $348 avg across 4 analysts.
Buy-rated share 20% → 20% over ~3 months (+0pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $1.75 | $2.62 | +49.7% |
| Apr 2026 | $1.97 | $1.89 | -4.1% |
| Feb 2026 | $2.57 | $2.51 | -2.3% |
| Oct 2025 | $2.30 | $2.26 | -1.7% |
| Jul 2025 | $1.93 | $2.61 | +35.2% |
| May 2025 | $1.73 | $2.54 | +46.8% |
| Feb 2025 | $2.86 | $2.90 | +1.4% |
| Oct 2024 | $1.28 | $2.01 | +57.0% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.9B— | $2.8B-4.1% | $2.7B-4.7% | $2.6B-3.9% | $2.6B+0.7% |
| EPS (dil.) | $140.83— | $-121.79-186.5% | $-21.82n/m | $-65.36n/m | $27.87n/m |
| Free Cash Flow | $536M— | $80M-85.0% | $218M+171.8% | $266M+22.0% | $375M+40.7% |
| Gross Margin | 56.1% | 55.9%-0.1pp | 53.4%-2.5pp | 53.7%+0.3pp | 52.0%-1.7pp |
| Operating Margin | 17.1% | 17.2%+0.1pp | 12.6%-4.6pp | 10.5%-2.2pp | 10.5%-0.0pp |
| Net Margin | 145.6% | -129.5%-275.0pp | -23.9%+105.6pp | -71.9%-48.0pp | 29.4%+101.3pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$136K over 180 days (0 open-market buys, 1 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 2.9%/yr (revenue basis).
Base free cash flow $286M (avg FY2023–FY2025; latest year $375M) · equity value $9.7B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 58 for Bio-Rad Laboratories indicates a moderately favorable outlook, driven by strong momentum with a 12-month return of 31.5% and a 3-month return of 48.3%. The stock's momentum score of 66 and risk score of 73 are notable positives, while its value score of 50 and growth score of 48 are more neutral, reflecting a P/E of 43.3 and revenue growth of 0.7%. The short-term score of 62 is slightly higher than the long-term score of 55, suggesting some near-term optimism.